Sign In
Buy BCAB
$3.29
-0.0900 (-2.66%)
At Close: Jul 31, 2026
BioAtla: Intriguing Science, New IPO, A Name To Watch
07:29am, Sunday, 07'th Feb 2021
BioAtla is developing selectively-targeting antibodies based on very interesting science. However, it is a new IPO, and current prices and cash reserves are not conducive to investment.
Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More
01:53pm, Saturday, 26'th Dec 2020
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying c
BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
04:00pm, Friday, 18'th Dec 2020
SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics
BioAtla Announces Pricing of Initial Public Offering
07:59pm, Tuesday, 15'th Dec 2020
SAN DIEGO, Dec. 15, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics
